|Benefit-Cost Summary Statistics Per Participant|
|Taxpayers||$496||Benefits minus costs||$2,773|
|Participants||$652||Benefit to cost ratio||$11.54|
|Others||$242||Chance the program will produce|
|Indirect||$1,647||benefits greater than the costs||59 %|
|Net program cost||($263)|
|Benefits minus cost||$2,773|
|Meta-Analysis of Program Effects|
|Outcomes measured||Treatment age||No. of effect sizes||Treatment N||Adjusted effect sizes(ES) and standard errors(SE) used in the benefit - cost analysis||Unadjusted effect size (random effects model)|
|First time ES is estimated||Second time ES is estimated|
Alcohol use disorder
Clinical diagnosis of alcohol use disorder or symptoms measured on a validated scale.
Adult use of cannabis that does not rise to the level of “disordered.”
Illicit drug use disorder
Clinical diagnosis of illicit drug use disorder or symptoms measured on a validated scale. When possible, we exclude cannabis/marijuana use disorder from this outcome.
|Detailed Monetary Benefit Estimates Per Participant|
|Affected outcome:||Resulting benefits:1||Benefits accrue to:|
|Alcohol use disorder||Property loss associated with alcohol abuse or dependence||$0||$0||$1||$0||$1|
|Illicit drug use disorder||Criminal justice system||$0||$0||$1||$0||$1|
|Labor market earnings associated with illicit drug abuse or dependence||$190||$446||$0||$0||$636|
|Health care associated with illicit drug abuse or dependence||$234||$36||$240||$117||$627|
|Mortality associated with illicit drugs||$72||$169||$0||$1,662||$1,903|
|Program cost||Adjustment for deadweight cost of program||$0||$0||$0||($132)||($132)|
|Detailed Annual Cost Estimates Per Participant|
|Annual cost||Year dollars||Summary|
|Program costs||$240||2012||Present value of net program costs (in 2018 dollars)||($263)|
|Comparison costs||$0||2012||Cost range (+ or -)||40 %|
Benefits Minus Costs
Benefits by Perspective
Taxpayer Benefits by Source of Value
|Benefits Minus Costs Over Time (Cumulative Discounted Dollars)|
|The graph above illustrates the estimated cumulative net benefits per-participant for the first fifty years beyond the initial investment in the program. We present these cash flows in discounted dollars. If the dollars are negative (bars below $0 line), the cumulative benefits do not outweigh the cost of the program up to that point in time. The program breaks even when the dollars reach $0. At this point, the total benefits to participants, taxpayers, and others, are equal to the cost of the program. If the dollars are above $0, the benefits of the program exceed the initial investment.|
Chen, W., Hong, Y., Zou, X., McLaughlin, M.M., Xia, Y., & Ling, L. (2013). Effectiveness of prize-based contingency management in a methadone maintenance program in China. Drug and Alcohol Dependence, 133(1), 270-274.
Groß, A., Marsch, L.A., Badger, G.J., & Bickel, W.K. (2006). A comparison between low-magnitude voucher and buprenorphine medication contingencies in promoting abstinence from opioids and cocaine. Experimental and Clinical Psychopharmacology, 14(2), 148-156.
Hagedorn, H.J., Noorbaloochi, S., Simon, A.B., Bangerter, A., Stitzer, M.L., Stetler, C.B., & Kivlahan, D. (2013). Rewarding early abstinence in Veterans Health Administration addiction clinics. Journal of Substance Abuse Treatment, 45(1), 109-117.
Hall, E.A., Prendergast, M.L., Warda, U., & Roll, J.M. (2009). Reinforcing abstinence and treatment participation among offenders in a drug diversion program: Are Vouchers Effective?. Criminal Justice and Behavior, 36(9), 935-953.
Hser, Y.I., Li, J., Jiang, H., Zhang, R., Du, J., Zhang, C., Zhang, B., ... Zhao, M. (2011). Effects of a randomized contingency management intervention on opiate abstinence and retention in methadone maintenance treatment in China. Addiction, 106(10), 1801-1809.
Iguchi, M.Y., Belding, M.A., Morral, A.R., Lamb, R.J., & Husband, S.D. (J1997). Reinforcing operants other than abstinence in drug abuse treatment: an effective alternative for reducing drug use. Journal of Consulting and Clinical Psychology, 65(3), 421-8.
Jones, H.E., Haug, N.A., Stitzer, M.L., & Svikis, D.S. (2000). Improving treatment outcomes for pregnant drug-dependent women using low-magnitude voucher incentives. Addictive Behaviors, 25(2), 263-267.
McCaul, M.E., Stitzer, M.L., Bigelow, G.E., & Liebson, I A. (1984). Contingency management interventions: effects on treatment outcome during methadone detoxification. Journal of Applied Behavior Analysis, 17(1), 35-43.
McDonell, M.G., Srebnik, D., Angelo, F., McPherson, S., Lowe, J.M., Sugar, A., Short, R.A., ... Ries, R.K. (2013). Randomized controlled trial of contingency management for stimulant use in community mental health patients with serious mental illness. The American Journal of Psychiatry, 170(1), 94-101.
Menza, T.W., Jameson, D.R., Hughes, J.P., Colfax, G.N., Shoptaw, S., & Golden, M.R. (2010). Contingency management to reduce methamphetamine use and sexual risk among men who have sex with men: a randomized controlled trial. Bmc Public Health, 10(1), 774.
Peirce, J.M., Petry, N.M., Stitzer, M.L., Blaine, J., Kellogg, S., Satterfield, F., Schwartz, M., ... Li, R. (2006). Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study. Archives of General Psychiatry, 63(2), 201-208.
Petry, N.M., Martin, B., Cooney, J.L., & Kranzler, H.R. (2000). Give them prizes, and they will come: Contingency Management for treatment of alcohol dependence. Journal of Consulting and Clinical Psychology, 68(2), 250-257.
Petry, N. M., Tedford, J., Austin, M., Nich, C., Carroll, K. M., & Rounsaville, B. J. (2004). Prize reinforcement contingency management for treating cocaine users: how low can we go, and with whom?. Addiction, 99(3), 349-360.
Petry, N.M., Peirce, J.M., Stitzer, M.L., Blaine, J., Roll, J.M., Cohen, A., Obert, J., ... Li, R. ( 2005). Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study. Archives of General Psychiatry, 62(10), 1148-1156.
Petry, N.M., Alessi, S.M., Marx, J., Austing, M., Tardif, M. 2005. Vouchers versus prizes: Contingency management treatment of substance abusers in community settings. Journal of Consulting and Clinical Psychology, 73(6), 1005-1014
Petry, N.M., Weinstock, J., Alessi, S.M., Lewis, M.W., & Dieckhaus, K. (2010). Group-based randomized trial of contingencies for health and abstinence in HIV patients. Journal of Consulting and Clinical Psychology, 78(1), 89-97.
Petry, N.M., Weinstock, J., & Alessi, S.M. (2011). A randomized trial of contingency management delivered in the context of group counseling. Journal of Consulting and Clinical Psychology, 79(5), 686-96.
Petry, N.M., Alessi, S.M., & Ledgerwood, D.M. (2012). Contingency management delivered by community therapists in outpatient settings. Drug and alcohol dependence, 122(1), 86-92.
Petry, N.M., Alessi, S.M., & Rash, C.J. (2013). A randomized study of contingency management in cocaine-dependent patients with severe and persistent mental health disorders. Drug and alcohol dependence, 130(1), 234-237.
Preston, K.L., Umbricht, A., & Epstein, D.H. (2002). Abstinence reinforcement maintenance contingency and one-year follow-up. Drug and Alcohol Dependence, 67(2), 125-137.
Roll, J.M., Chudzynski, J., Cameron, J.M., Howell, D.N., & McPherson, S. (2013). Duration effects in contingency management treatment of methamphetamine disorders. Addictive Behaviors, 38(9), 2455-2462.
Rowan-Szal, G.A.P.D., Joe, G.W.E.D., Hiller, M. L.P.D., & Simpson, D.D.P.D. (1997). Increasing Early Engagement in Methadone Treatment. Journal of Maintenance in the Addictions, 1(1), 49-61.
Rowan-Szal, G.A., Bartholomew, N.G., Chatham, L.R., & Simpson, D.D. (2005). A combined cognitive and behavioral intervention for cocaine-using methadone clients. Journal of Psychoactive Drugs, 37(1), 75-84.
Tracy, K., Babuscio, T., Nich, C., Kiluk, B., Carroll, K.M., Petry, N.M., & Rounsaville, B.J. (2007). Contingency Management to Reduce Substance Use in Individuals Who are Homeless with Co-Occurring Psychiatric Disorders. The American Journal of Drug and Alcohol Abuse, 33(2), 253-258.